DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients

DARA BioSciences, Inc. (Nasdaq:DARA) announced today additional positive results from its successfully completed KRN5500 Phase 2a Clinical Study for treatment of neuropathic pain in patients with cancer. Statistically significant primary endpoint results were released earlier.

More than 80% of patients in this clinical study had allodynia, which is an abnormal pain response to normally non-painful stimuli, such as light touch or temperature changes. Even the light pressure of clothing against the skin or a cold breeze can cause severe pain in patients with neuropathic pain.  Clinicians conducted 2 weekly examinations to determine if KRN5500 was effective in reducing allodynia.  For both tests, patients rated their pain on a Numeric Rating Scale of 1 to 10 (1 = no pain/10 = worst pain imaginable), both before the targeted area was stimulated and right afterward. 

The KRN5500 treatment group showed a larger median decrease in pain associated with both touch and cold (both touch and cold 33%) compared to placebo (0 and 8%, respectively).

DARA also announced that over the past 12 months, it has expanded its patent portfolio by 11 US and Foreign granted patents. Today, DARA has a portfolio of over 80 granted patents worldwide further strengthening its intellectual property position.